According to a recent study from Keck Medical of USC, men 45 and older are now more likely to have metastatic prostate cancer than they were five years ago. This finding is in line with recommendations against annual prostate cancer screenings.
“This study is the first to document a continued rise in metastatic prostate cancer using the most up-to-date population dataset,” said Mihir M. Desai, MD, MPH, a urologist with Keck Medicine and co-lead author of the study. “The discovery has important ramifications for men because prostate cancer when caught early, typically through a screening, is very treatable and often curable.”
Desai is also a professor of clinical urology at the Keck School of Medicine of USC and an associate member of the USC Norris Comprehensive Cancer Center, part of Keck Medicine.
In the U.S., prostate cancer screenings using the prostate-specific antigen (PSA) first became commonplace approximately 30 years ago. PSA levels are measured during PSA screenings, and excessive levels may be a sign of malignancy.
Prostate cancer fatalities and metastatic prostate cancer both decreased once screenings were implemented. However, the dangers of overdiagnosis and overtreatment of low-risk prostate cancer outweighed the advantages of frequent testing.
In 2008, the United States Preventive Services Task Force (USPSTF), a leading national organization in disease prevention and evidence-based medicine, recommended against routine PSA screening for men older than 75. This was followed by a recommendation against screening for all men in 2012.
According to research, men of all ages and races had less prostate cancer screenings after the recommendations changed.
This study is the first to document a continued rise in metastatic prostate cancer using the most up-to-date population dataset. The discovery has important ramifications for men because prostate cancer when caught early, typically through a screening, is very treatable and often curable.
Mihir M. Desai
Researchers at Keck Medical wanted to compare trends in metastatic prostate cancer before and after the USPSTF advice against testing.
They identified men 45 and older with a diagnosis of invasive prostate cancer from 2004-2018 through the Surveillance, Epidemiology and End Results (SEER) Program cancer incidence database.
From 2004-2018, the last year for which data was available, more than 836,000 prostate cancer patients 45 or older were recorded in the SEER database. Of these, 26,642 cases of metastatic prostate cancer were reported in men 45-74, and 20,507 cases in men 75 or older.
Among the 45-74 age group, the incidence rate of metastatic prostate cancer remained stable during 2004-2010, then increased 41% during 2010-2018. For men 75 and older, the incidence rate decreased in 2004-2011, then increased 43% from 2011-2018. For both age groups, the increases were across all races.
The researchers point out that these increases contrast with the declining incidence trends of metastatic prostate cancer between 2004 and 2009, just before the USPSTF ceased advising men to get regular PSA tests.
The use of new, cutting-edge diagnostic and staging tools that are better able to detect low-volume (less invasive) metastatic prostate cancer is one of the potential contributing factors that the authors discuss in addition to the possibility that other factors besides the change in screening recommendations in 2008 and 2012 may have contributed to the rise in cancer cases.
Nonetheless, they come to the conclusion that as such techniques are uncommon and often not employed for early cancer detection, they are not likely to have a significant impact on the results.
“This data is very important as it indicates the need to constantly reassess the impact of policy decisions,” said Giovanni Cacciamani, MD, MSc, co-lead author of the study, an assistant professor of research urology and radiology at the Keck School and an associate member of USC Norris. “Otherwise, we may see a continued rise in metastatic prostate cancer.”
The original concerns for stopping the screenings that they led to overdiagnosis and overtreatment of low-risk prostate cancer may also be outdated, say the authors.
“Urologic centers of excellence, including USC Urology, are continually researching ways to leverage technologies to optimize patient outcomes and decrease side effects of treatment,” said Inderbir Gill, MD, chairman of the Catherine and Joseph Aresty Department of Urology, distinguished professor of urology at the Keck School, executive director of the USC Institute of Urology and a member of USC Norris.
“More refined strategies, including biomarkers and magnetic resonance imaging, have already increased detection of clinically significant cancers, while active surveillance is increasingly used for low-risk and favorable intermediate-risk disease, thus mitigating the risks of overtreatment.”
Other Keck Medicine study authors include Juanjuan Zhang, a statistician at the Keck School; Lihua Liu, PhD, associate professor of clinical population and public health sciences at the Keck School, director, and principle investigator of the SEER Program and a member of USC Norris; and Andre Abreu, MD, a urologist with Keck Medicine who directs the Center for Targeted Biopsies & Focal Therapy at the USC Institute of Urology.
